Business Wire

First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Share

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.

Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far this year, with a focus on new modalities such as protein degraders, antimicrobial resistance, regenerative medicine, oncology and data science.

Fueled by ongoing strong demand for the company’s human heart failure, diabetes and respiratory treatments, and its products for pets, currency-adjusted net sales rose by 9.5 percent to 11.2 billion EUR.

“Despite a volatile economic environment, we were able to supply more patients with the treatments that make a difference to them, while advancing our pipeline in Human Pharma as well as in Animal Health striving to transform lives where medical need is high,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.

Boehringer Ingelheim has earmarked 25 billion EUR for investments in R&D and an additional 7 billion EUR for new production technologies over the next five years. The company anticipates running eight active human medicines registrational trials by the end of the year, with the potential of bringing 15 new products to patients by 2027.

“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We will continue to focus on and invest in our most promising assets to bring the best value to patients.”

Net sales in Human Pharma were up 11.8 percent (currency-adjusted) during the first six months of 2022 at 8.4 billion EUR, mainly driven by diabetes treatment of the JARDIANCE® family at 2.5 billion EUR and the respiratory medicine OFEV® at 1.5 billion EUR.

Growth in the Animal Health business amounted to 1.2 percent (currency-adjusted) to 2.4 billion EUR. The business was impacted by challenging market conditions including inflation, COVID-19 lockdowns, outbreaks of African Swine Fever and supply chain constraints. Net sales of NEXGARD®, a parasiticide for dogs, increased 13.7 percent (currency-adjusted) to 593 million EUR, while HEARTGARD®, which prevents heartworm disease in dogs, rose 4.4 percent to 197 million EUR.

For the remainder of the year Boehringer Ingelheim is anticipating regulatory updates for Spesolimab, a potential treatment for flares in generalized pustular psoriasis (GPP), a rare, life-threatening neutrophilic skin disease. The company will also present promising data on JARDIANCE® for the treatment of patients with chronic kidney disease. In addition, major product launches are expected for Animal Health in 2022 and 2023.

Click here for the full release: https://www.boehringer-ingelheim.com/about-us/corporate-profile/boehringer-ingelheim-2022-half-year-results

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Harro Ten Wolde
Head of Global Media Relations
Email: harro.ten_wolde@boehringer-ingelheim.com
Phone Number: +49 (6132) 77-181352

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Study From Egon Zehnder and Kearney Debunks the Myth of a Workplace Generational Divide28.9.2022 16:00:00 CEST | Press release

Egon Zehnder, the world’s preeminent leadership advisory firm, in partnership with Kearney, a leading global management consulting firm, today released findings from a new survey with over 8,000 respondents from eight different countries dismissing the myth of a generation divide in the workplace and showing that despite what is often believed, Gen Z, Millennials, Gen X and Boomers are more alike than different when it comes to workplace matters. The survey, titled “Different Generations, Same Ideals: What Workers of All Ages Value in their Jobs,” analyzed the similarities and differences among generations and found that they share more commonalities, especially when it comes to personal well-being, work-life balance, and desired traits from leadership. The most notable difference between the generations is how each group defines and plans to achieve their career desires. Key Findings from the survey include: Personal well-being, stability, and work-life balance matter more than money

BYD Announces Pre-sale Prices of European Passenger Car Range28.9.2022 15:35:00 CEST | Press release

BYD announces the pre-sale prices of its new European passenger car range. The world’s leading manufacturer of new energy vehicles and power batteries immediately introduces three full-electric passenger vehicles which will be delivered to Norway, Sweden, Denmark, the Netherlands, Belgium, Luxembourg and Germany. Before the end of the year customers in France and the United Kingdom will also have access to BYD’s zero-emission vehicles. After that, more dealers will be appointed supporting BYD’s plans to cover all major markets in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005587/en/ BYD Europe Product Premiere 2022 The pre-sale price for the BYD ATTO 3 is € 38,000. The BYD HAN and TANG pre-sale prices are € 72,000. These pre-sale prices apply to Germany as a reference for Europe and may differ from country to country. The three full-electric BYD vehicles are technologically advanced and well-suited to the e

Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany28.9.2022 15:27:00 CEST | Press release

Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany. The new facility will focus on the manufacture of SPECT products and radiopharmaceutical products for radioligand therapy(*) such as Gallium-68 generator and n.c.a Lutetium-177. Developed by Monrol R&D teams, these products are widely used in the production of radiopharmaceuticals for cancer patients. The facility will also have a dedicated division for state-of-the art cGMP Contract Development and Manufacturing Organization (CDMO) services. Monrol plans to make the site a center of excellence for both radiopharmaceutical production and scientific and industry collaborative efforts to create innovations. The facility is expected to be up and running by 2026 at an estimated cost of around 30 million euros. (*) Targeted radioligand therapy is an innovative approach to cancer treatment that is considered to

Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations28.9.2022 15:00:00 CEST | Press release

Fore Biotherapeutics (Fore Bio), a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to FORE8934, its investigational, novel, small-molecule, orally available inhibitor for the treatment of patients with cancers harboring BRAF Class 1 (V600) and Class 2 (including fusions) alterations who have exhausted prior therapies. The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A drug that receives Fast Track designation may become eligible for Accelerated Approval, Priority Review, or Rolling Review if relevant criteria are met. “The FDA's Fast Track Designation for FORE8394 underscores the urgent need faced by patients with advanced BRAF-muted cancers who have no other options,” said Stacie

Quectel Announces New SC680A LTE Smart Module to Drive Digital Transformation and Machine Vision AI Applications28.9.2022 15:00:00 CEST | Press release

Quectel Wireless Solutions, a global IoT solutions provider, today announces that it has released its new SC680A smart module which features broad connectivity options including LTE Cat 6, Wi-Fi 802.11ac and Bluetooth 5.0 with powerful system performance and rich multimedia functions. The SC680A smart module is targeted towards mid-tier IoT devices including POS and payment terminals, industrial handhelds for logistics and warehousing, in-vehicle infotainment and dashcam solutions as well as micro-mobility applications and small electric cars. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005031/en/ Quectel's new SC680A LTE smart module (Photo: Business Wire) “We are excited to introduce another highly integrated smart module which gives global customers more flexibility in their IoT device designs,” said Norbert Muhrer, President and CSO of Quectel. “It enables a variety of industrial and consumer IoT verticals with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom